Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE (2010) Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Circ Cardiovasc Qual Outcomes 3(2):204–211. https://doi.org/10.1161/CIRCOUTCOMES.109.880450

Article  PubMed  Google Scholar 

Roth GA, Poole JE, Zaha R, Zhou W, Skinner J, Morden NE (2016) Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation. J Am Coll Cardiol 67(9):1062–1069. https://doi.org/10.1016/j.jacc.2015.12.046

Article  PubMed  PubMed Central  Google Scholar 

Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC (2015) Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. Eur Heart J Cardiovasc Pharmacother 1(3):182–188. https://doi.org/10.1093/ehjcvp/pvv016

Article  CAS  PubMed  Google Scholar 

Martens P, Verbrugge FH, Nijst P, Bertrand PB, Dupont M, Tang WH et al (2017) Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy. J Card Fail 23(8):597–605. https://doi.org/10.1016/j.cardfail.2017.03.001

Article  CAS  PubMed  Google Scholar 

Martens P, Dupont M, Mullens W (2020) Reduced occurrence of appropriate therapy for ventricular arrhythmias after beta-blocker uptitration following implant of a primary prevention CRT-defibrillator. Acta Cardiol 75(1):49–53. https://doi.org/10.1080/00015385.2018.1547469

Article  PubMed  Google Scholar 

Salimian S, Deyell MW, Andrade JG, Chakrabarti S, Bennett MT, Krahn AD et al (2021) Heart failure treatment in patients with cardiac implantable electronic devices: opportunity for improvement. Heart Rhythm O2. 2(6):698–709

Article  PubMed  PubMed Central  Google Scholar 

Jorsal A, Pryds K, McMurray JJV, Wiggers H, Sommer A, Nielsen JC et al (2020) Optimizing heart failure treatment following cardiac resynchronization therapy. Clin Res Cardiol 109(5):638–645. https://doi.org/10.1007/s00392-019-01553-4

Article  CAS  PubMed  Google Scholar 

McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al (2021) CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37(4):531–546. https://doi.org/10.1016/j.cjca.2021.01.017

Article  PubMed  Google Scholar 

Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL et al (2021) 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol 77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022

Article  PubMed  Google Scholar 

Parikh KS, Lippmann SJ, Greiner M, Heidenreich PA, Yancy CW, Fonarow GC et al (2017) Scope of sacubitril/valsartan eligibility after heart failure hospitalization: findings from the GWTG-HF Registry (Get With The Guidelines-Heart Failure). Circulation 135(21):2077–2080

Article  PubMed  PubMed Central  Google Scholar 

Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al (2008) Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52(3):190–199

Article  CAS  PubMed  Google Scholar 

Vaduganathan M, Greene SJ, Zhang S, Grau-Sepulveda M, DeVore AD, Butler J et al (2021) Applicability of US food and drug administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in us clinical practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. JAMA cardiol 6(3):267–275

Article  Google Scholar 

Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72(4):351–366

Article  PubMed  Google Scholar 

DeVore AD, Hill CL, Thomas L, Sharma PP, Albert NM, Butler J et al (2018) Patient, provider, and practice characteristics associated with sacubitril/valsartan use in the United States. Circ Heart Fail 11(9):e005400. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005400

Article  PubMed  Google Scholar 

Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M et al (2010) Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail 3(5):596–605. https://doi.org/10.1161/CIRCHEARTFAILURE.109.912683

Article  PubMed  Google Scholar 

Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V et al (2020) Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J of Heart Fail 22(12):2349–2369

Article  Google Scholar 

D’Onofrio A, Palmisano P, Rapacciuolo A, Ammendola E, Calo L, Ruocco A et al (2017) Effectiveness of a management program for outpatient clinic or remote titration of beta-blockers in CRT patients: The RESTORE study. Int J Cardiol 236:290–295. https://doi.org/10.1016/j.ijcard.2017.02.015

Article  PubMed  Google Scholar 

Bristow M, Saxon L, Boehmer J, Krueger S, Kass D, De MT et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140–2150

Article  CAS  PubMed  Google Scholar 

Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549

Article  CAS  PubMed  Google Scholar 

Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GM, Dahlström U et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20(9):1326–1334

Article  CAS  PubMed  Google Scholar 

Aranda JM Jr, Woo GW, Conti JB, Schofield RS, Conti CR, Hill JA (2005) Use of cardiac resynchronization therapy to optimize beta-blocker therapy in patients with heart failure and prolonged QRS duration. Am J Cardiol 95(7):889–891. https://doi.org/10.1016/j.amjcard.2004.12.023

Article  CAS  PubMed  Google Scholar 

Adlbrecht C, Hulsmann M, Gwechenberger M, Strunk G, Khazen C, Wiesbauer F et al (2009) Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment. Eur J Clin Invest 39(12):1073–1081. https://doi.org/10.1111/j.1365-2362.2009.02217.x

Article  PubMed  Google Scholar 

Schmidt S, Hurlimann D, Starck CT, Hindricks G, Luscher TF, Ruschitzka F et al (2014) Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J 35(16):1051–1060. https://doi.org/10.1093/eurheartj/eht514

Article  CAS  PubMed  Google Scholar 

Mantziari L, Guha K, Khalique Z, McDonagh T, Sharma R (2012) Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis. Am J Cardiol 109(11):1619–1625. https://doi.org/10.1016/j.amjcard.2012.01.387

Article  CAS  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(36):3599–3726

Article  CAS  PubMed  Google Scholar 

Greene SJ, Khan MS (2021) Quadruple medical therapy for heart failure: medications working together to provide the best care. J Am Coll Cardiol 77(11):1408–1411

Article  PubMed  Google Scholar 

Bhatt AS, Vaduganathan M, Claggett BL, Liu J, Packer M, Desai AS et al (2021) Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail 23(9):1518–1524

Article  CAS  PubMed  Google Scholar 

Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2021) Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol 77(11):1397–1407

Article  CAS  PubMed  Google Scholar 

Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P et al (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. Heart Fail 8(3):188–198

Google Scholar 

Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 41(36):3402–3418

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A et al (2017) A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Failure 5(3):216–225. https://doi.org/10.1016/j.jchf.2016.12.011

Article  PubMed  Google Scholar 

Wever-Pinzon O, Drakos SG, Fang JC (2015) Team-based care for advanced heart failure. Heart Fail Clin 11(3):467–477

Article  PubMed  Google Scholar 

Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM (1995) A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333(18):1190–1195

Article  CAS  PubMed  Google Scholar 

Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP et al (2017) The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 19(11):1401–1409. https://doi.org/10.1002/ejhf.838

Article  PubMed  Google Scholar 

Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A et al (2020) Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations? JACC Heart Failure